Usual community pharmacy workflow, whereby patients might see a pharmacist at the end of the dispensing process, is not conducive to proactive patient-centred care. The objective of this study was to evaluate the impact of the “Pharmacist First” (P1st) workflow model on blood pressure and glycemic control in patients with hypertension and/or diabetes. This retrospective review was set in 2 community pharmacies that use the P1st model in the Greater Edmonton Region. The population entailed patients with hypertension and/or type 1 or 2 diabetes who received care via the P1st workflow model. The P1st workflow model places the patient in immediate contact with the pharmacist. The pharmacist first assesses prescription appropriateness, reviews relevant laboratory tests, discusses chronic disease control and addresses any questions or concerns the patient has before passing the prescription to be filled by a technician. This allows issues or concerns to be identified and addressed up front, rather than waiting until the prescription is filled and the patient is ready to leave the pharmacy. The primary outcome assessed in this study was change in blood pressure and/or A1C from baseline to the last follow-up visit. We reviewed 215 patient records. The mean age was 69.4 years (standard deviation 12.5), 51.2% of patients were male, 57.7% had hypertension, 5.6% had diabetes, and 36.7% had both. Median follow-up time was 4.2 months (interquartile range 2.5 -9.3). In 203 patients with hypertension, systolic blood pressure was reduced from 139.83 mmHg to 131.26 mmHg ( p < 0.001) and diastolic blood pressure from 80.26 mmHg to 76.86 mmHg ( p < 0.001). In 87 patients with diabetes, A1C changed from 7.4% to 7.2% ( p = ns). The P1st workflow model demonstrated significant improvements in blood pressure. Further investigation is needed to evaluate the effectiveness of this model with a control group, longer follow-up and evaluation of the patient experience.

In Canada, the National Advisory Committee on Immunization (NACI) makes recommendations for vaccination. 1,2 However, vaccines that are publicly funded vary by province and territory, largely based on cost effectiveness and budget capacity, rather than clinical indication and vaccine effectiveness. Using their full scope of practice, pharmacists have a unique opportunity to offer recommended protection against vaccine-preventable diseases to patients. Pneumococcal vaccines Disease burden Streptococcus pneumoniae is a bacterium that causes invasive pneumococcal disease (IPD), such as bacteremia and meningitis, and is a common cause of community-acquired pneumonia (CAP). There are over 90 serotypes recognized worldwide, 15 of which cause the majority of disease. S. pneumoniae can spread from person to person by droplets from the nose or mouth, by sneezing or coughing. 3